Rituximab in Autoimmune CNS Disease
Investigators at University of Sydney, Australia, and 14 international centers assessed the utility and safety of rituximab in 144 children (median age 8 years, range 0.7-17; 103 female) with autoimmune and inflammatory disorders of the CNS.
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | |
| Опубликовано: |
Pediatric Neurology Briefs Publishers,
2014-08-01T00:00:00Z.
|
| Предметы: | |
| Online-ссылка: | Connect to this object online. |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|
| Итог: | Investigators at University of Sydney, Australia, and 14 international centers assessed the utility and safety of rituximab in 144 children (median age 8 years, range 0.7-17; 103 female) with autoimmune and inflammatory disorders of the CNS. |
|---|---|
| Примечание: | 1043-3155 2166-6482 10.15844/pedneurbriefs-28-8-7 |